Baxter CEO Says A Rival's Supply Problem Is 'Not A Small Piece' Of 12% Advanced Surgery Growth

Andrew Hider also warned that comparisons will toughen for the $342 million unit, and for drug compounding, which grew 9%.

Share
Baxter CEO Says A Rival's Supply Problem Is 'Not A Small Piece' Of 12% Advanced Surgery Growth

Baxter's advanced surgery business grew 12% to $342 million in the third quarter, and CEO Andrew Hider said on the company's earnings call Thursday that a competitor's supply trouble was a meaningful part of it. He added that next year's comparison will be harder.

Three drivers, one of them a rival's stumble

Asked by a Citi analyst what drove the double-digit acceleration, and whether any one-time item was in it, Hider started with the market, which he said is growing at low to mid single digits. He then pointed to stronger growth in some regions.

The third factor, Hider said, was that "there's been a competitor that's had a challenge with supply," and he called it "not a small piece" of the growth. Because of Baxter's operational performance, he said, the company has been able to "maximize this impact."

Hider said the year-over-year comparison will be more challenging, and that Baxter will stay very close to that single supply piece. Chief Financial Officer John Rogers said the unit's results reflected strong demand and higher volumes of hemostats and sealants, strong commercial execution across regions and steady procedure volumes.

Tougher comps for two growth engines

Kevin Moran, Baxter's head of investor relations, told an Evercore ISI analyst that comparisons for both advanced surgery and drug compounding will get increasingly difficult. Drug compounding sales grew 9% in the quarter, Rogers said. Moran said both businesses should keep growing in the fourth quarter, though perhaps not at the same magnitude as lately.

Baxter, which makes products including IV solutions, infusion systems, generic injectable drugs and hospital beds, sold about $3 billion overall, up 5% on both a reported and organic basis. Adjusted earnings were 58 cents a share, down 16% on a higher tax rate. Management raised its 2026 organic sales growth outlook to 3% to 4%, from 2% to 3%.

Guidance comes in February

Baxter has not set a 2027 outlook. Rogers, who joined as CFO on October 1, said detailed guidance will come with fourth-quarter results in February, and he listed moving parts: inflation, tariffs, the end of services for Vantive by the end of January 2027, planned product exits and the shutdown of cephalosporin production, which contributes about $50 million in sales and $30 million in operating income in 2026.

Baxter's February guidance will show how much of advanced surgery's growth management plans to carry into 2027.

Sources

More on Baxter International

All Baxter International (BAX) coverage →